XML 42 R24.htm IDEA: XBRL DOCUMENT
v3.19.1

Market Concentrations | 12 Months Ended
--- | ---
Dec. 31, 2018
Risks and Uncertainties [Abstract] |
Market Concentrations | Market Concentrations The Company currently focuses on the acquisition, development and commercialization of branded prescription products for the hospital acute care, gastroenterology, and oncology supportive care markets. The Company’s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company’s cash equivalents consist primarily of money market funds. Certain bank deposits may at times be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation. The Company’s primary customers are wholesale pharmaceutical distributors in the U.S. Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:
|  | 2018 |  | 2017 |  | 2016
Customer 1 |  | 26% |  |  | 25% |  |  | 22% |
Customer 2 |  | 24% |  |  | 22% |  |  | 28% |
Customer 3 |  | 25% |  |  | 25% |  |  | 29% |
Customer 4 |  | *% |  |  | *% |  |  | 10% |
Customer 5 |  | 11% |  |  | *% |  | *%
*: less than 10% of total |  |  |  |  |  |
The Company’s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 78% and 53% at December 31, 2018 and 2017, respectively.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration